Literature DB >> 20497940

Long-term management with octreotide or cabergoline in ectopic corticotropin hypersecretion: case report and literature review.

Oscar D Bruno1, Karina Danilowicz, Marcos Manavela, Daniela Mana, Maria A Rossi.   

Abstract

OBJECTIVE: To describe the corticotropin response to long-term octreotide or cabergoline administration in a patient with ectopic corticotropin secretion who underwent adrenalectomy.
METHODS: We describe the clinical, radiologic, and biochemical findings of the study patient over the course of 18 years.
RESULTS: A 40-year-old woman was evaluated for Cushing syndrome. On the basis of biochemical indices, Cushing disease was diagnosed and pituitary exploration was performed. No cure was achieved. Computed tomography of the chest revealed a right lung nodule due to a lung carcinoid tumor that was then surgically excised. Because of persistent hypercortisolism, total adrenalectomy was performed. Subsequently, corticotropin levels rose dramatically and hyperpigmentation developed while serum cortisol was in the reference range. The patient was treated with octreotide for 3 years and then with cabergoline for 8 years. While taking octreotide, corticotropin values decreased, accompanied by depigmentation and development of signs of adrenal insufficiency, which led to the reinstitution of supplemental hydrocortisone. Cabergoline induced a similar long-lasting effect on the clinical and biochemical parameters observed. Eight years later, she is still treated with cabergoline, and no lung tumor has been detected.
CONCLUSIONS: In this patient with ectopic Cushing syndrome, treatment with either octreotide or cabergoline markedly reduced corticotropin levels and hyperpigmentation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497940     DOI: 10.4158/EP09286.CR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  [Ectopic hormone secretion by neuroendocrine tumors].

Authors:  C Hubold; G Brabant
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

2.  Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.

Authors:  Marcos Paulo Manavela; K Danilowicz; O D Bruno
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 3.  PET imaging in ectopic Cushing syndrome: a systematic review.

Authors:  Prasanna Santhanam; David Taieb; Luca Giovanella; Giorgio Treglia
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

4.  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.

Authors:  Claudia Pivonello; Panagoula Rousaki; Mariarosaria Negri; Maddalena Sarnataro; Maria Napolitano; Federica Zito Marino; Roberta Patalano; Maria Cristina De Martino; Concetta Sciammarella; Antongiulio Faggiano; Gaetano Rocco; Renato Franco; Gregory A Kaltsas; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

5.  Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease.

Authors:  Jacob S Daniel; Jyothish P Govindan; Chandan Kamath; Charles D'Souza; Mohamed A Adlan; Lakdasa D Premawardhana
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2014-05-01

Review 6.  Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Authors:  A G Ambrogio; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2016-04-16       Impact factor: 4.256

Review 7.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.